AU Patent

AU2018255510B2 — Liquid crystalline dosage form for administering a statin

Assigned to Cubopharm Pty Ltd · Expires 2024-05-30 · 2y expired

What this patent protects

A composition including an amphiphilic compound capable of self-assembling into liquid crystalline particles and a statin for systemic administration via oral mucosa. A method of lowering blood cholesterol levels in a subject comprising administering the self-assembling liquid cr…

USPTO Abstract

A composition including an amphiphilic compound capable of self-assembling into liquid crystalline particles and a statin for systemic administration via oral mucosa. A method of lowering blood cholesterol levels in a subject comprising administering the self-assembling liquid crystalline particles and statin via oral mucosa. Preferred dosage forms result in prolonged release of the statin.

Drugs covered by this patent

Patent Metadata

Patent number
AU2018255510B2
Jurisdiction
AU
Classification
—
Expires
2024-05-30
Drug substance claim
No
Drug product claim
No
Assignee
Cubopharm Pty Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.